Biotech firm working on Covid-19 vaccine raises $20 million
February 15, 2021 - Oragenics Inc., a Tampa biotech company that’s working on a Covid-19 vaccine, has raised $20 million via sale of stock that was facilitated by Alliance Global Partners, a New York investment and advisory firm. The company also received $1.9 million from the exercise of common stock warrants. According to a press release, Oragenics has given a notice for the redemption of all outstanding shares of the company’s Series C, non-convertible, preferred stock, which President and CEO Alan Joslyn said will raise an additional $5.6 million. “We are delighted that we were able to raise capital to fund our operations through a number of anticipated key value-creating milestones towards the initiation of the Phase 2 clinical trial of our SARS CoV-2 vaccine, Terra CoV-2,” Joslyn stated in the release.